These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 17373187)

  • 61. Redefining clinical response in psoriasis: targeting the pathological basis of disease.
    Ortonne JP
    J Drugs Dermatol; 2004; 3(1):13-20. PubMed ID: 14964742
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy.
    Salame N; Ehsani-Chimeh N; Armstrong AW
    Arch Dermatol Res; 2019 Aug; 311(6):453-460. PubMed ID: 31020408
    [TBL] [Abstract][Full Text] [Related]  

  • 63. TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey.
    Atakan N; Yazici AC; Özarmağan G; İnalÖz HS; Gürer MA; Sabuncu İ; Kİremİtçİ Ü; Alper S; Aytekİn S; Arican Ö; Polat M; Doğan S; Aldİnç E
    J Dermatol; 2016 Mar; 43(3):298-304. PubMed ID: 26365805
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Review of safety and efficacy of approved systemic psoriasis therapies.
    Kaushik SB; Lebwohl MG
    Int J Dermatol; 2019 Jun; 58(6):649-658. PubMed ID: 30246393
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
    Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
    Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biologic therapies for moderate to severe psoriasis are not interchangeable.
    Puig L
    Actas Dermosifiliogr; 2014 Jun; 105(5):483-6. PubMed ID: 24094516
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
    Wright NA; Piggott CD; Eichenfield LF
    Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
    [No Abstract]   [Full Text] [Related]  

  • 68. [Psoriasis].
    Navarini AA; Trüeb RM
    Ther Umsch; 2010 Apr; 67(4):153-65. PubMed ID: 20336615
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Biologics for psoriasis.
    Dubin DB; Tanner W; Ellis R
    Nat Rev Drug Discov; 2003 Nov; 2(11):855-6. PubMed ID: 14702956
    [No Abstract]   [Full Text] [Related]  

  • 70. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Topical treatments in psoriasis: today and tomorrow.
    Bos JD; Spuls PI
    Clin Dermatol; 2008; 26(5):432-7. PubMed ID: 18755361
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
    Takeshita J; Gelfand JM; Li P; Pinto L; Yu X; Rao P; Viswanathan HN; Doshi JA
    J Invest Dermatol; 2015 Dec; 135(12):2955-2963. PubMed ID: 26214380
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Review of home phototherapy.
    Rajpara AN; O'Neill JL; Nolan BV; Yentzer BA; Feldman SR
    Dermatol Online J; 2010 Dec; 16(12):2. PubMed ID: 21199628
    [TBL] [Abstract][Full Text] [Related]  

  • 74. OMERACT II: the biologics perspective.
    Strand V
    J Rheumatol; 1995 Jul; 22(7):1415-7. PubMed ID: 7562788
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
    Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.
    Yelverton CB; Kulkarni AS; Balkrishnan R; Feldman SR
    Manag Care Interface; 2006 Jan; 19(1):33-6, 39. PubMed ID: 16453993
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial.
    Ortonne JP; Ganslandt C; Tan J; Nordin P; Kragballe K; Segaert S
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):919-26. PubMed ID: 19453810
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: the secuence study.
    Hernánz JM; Sánchez-Regaña M; Izu R; Mendiola V; García-Calvo C
    Actas Dermosifiliogr; 2012 Dec; 103(10):897-904. PubMed ID: 23157919
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Insurance Coverage of Biologics for Moderate-to-Severe Psoriasis: A Retrospective, Observational 5-Year Chart Review.
    Abdelnabi M; Patel A; Rengifo-Pardo M; Ehrlich A
    Am J Clin Dermatol; 2016 Aug; 17(4):421-4. PubMed ID: 27283586
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care.
    Stein KR; Pearce DJ; Feldman SR
    Semin Cutan Med Surg; 2005 Mar; 24(1):52-7. PubMed ID: 15900799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.